Converge Bio
Generative AI Platform for Biological Engineering
StartupConverge Bio is a Tel Aviv-Yafo-based startup in the Health Tech & Life Sciences sector, established in 2024. Generative AI Platform for Biological Engineering. The company has raised a total of $5.5M across 2 funding rounds, currently at the Seed stage. Converge Bio was founded by Oded Kalev. Key investors include TLV Partners. The company has 11-50 employees. Core technologies: Artificial Intelligence, Generative AI.
With $5.5M in total funding, Converge Bio is a Seed-stage company operating in Health Tech & Life Sciences. The company follows a B2B business model. Product stage: R&D.
- StageSeed
- ProductR&D
- ModelB2B
- Employees11-50
- HQTel Aviv-Yafo
- DistrictCenter District
- Last Round$5.5M
- TLV Partners
Oded KalevCo-founder & CTO
2 articles covered by sources including www.calcalistech.com,
www.prnewswire.com.
What does Converge Bio do?
Converge Bio is aiming is revolutionize biological R&D by creating a Generative AI platform for DNA, RNA, and protein sequences.
How much funding has Converge Bio raised?
Converge Bio has raised $5.5M in total funding across 2 rounds. The company is currently at the Seed stage. Key investors include TLV Partners.
Who founded Converge Bio?
Converge Bio was founded in 2024 by Oded Kalev (Co-founder & CTO).
What sector is Converge Bio in?
Converge Bio operates in Health Tech & Life Sciences, Pharma & Medical Biotechnology, with core technologies in Artificial Intelligence, Generative AI. Target customers: Healthcare & Life Sciences, Life Sciences, Biotechnology, Pharmaceuticals.
Where is Converge Bio located?
Converge Bio is based in Daniel Frisch St, Tel Aviv-Yafo, Israel, Center District.